All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of ...
StockStory.org on MSN19h
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals StocksAs the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...
We recently published a list of What Did Jim Cramer Say About These 19 Stocks Recently? In this article, we are going to take ...
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...
Explore why Recursion Pharmaceuticals' AI-driven drug discovery faces challenges in revenue growth, governance, and investor ...
ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to ...
Fennec Pharmaceuticals shares were down after the company reported fourth-quarter results. The stock was recently down 10% to $6.20 and is down about 2% this year.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results